Conflict of interest: No
Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy
Article first published online: 27 AUG 2014
© 2014 Wiley Periodicals, Inc.
American Journal of Hematology
Volume 89, Issue 12, pages 1121–1131, December 2014
How to Cite
Solh, M., Yohe, S., Weisdorf, D. and Ustun, C. (2014), Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy. Am. J. Hematol., 89: 1121–1131. doi: 10.1002/ajh.23821
- Issue published online: 19 NOV 2014
- Article first published online: 27 AUG 2014
- Accepted manuscript online: 2 AUG 2014 03:50AM EST
- Manuscript Accepted: 30 JUL 2014
- Manuscript Revised: 25 JUL 2014
- Manuscript Received: 23 JUN 2014
Core binding factor acute myelogenous leukemia (CBF AML) constitutes 15% of adult AML and carries an overall good prognosis. CBF AML encodes two recurrent cytogentic abnormalities referred to as t(8;21) and inv (16). The two CBF AML entities are usually grouped together but there is a considerable clinical, pathologic and molecular heterogeneity within this group of diseases. Recent and ongoing studies are addressing the molecular heterogeneity, minimal residual disease and targeted therapies to improve the outcome of CBF AML. In this article, we present a comprehensive review about CBF AML with emphasis on molecular heterogeneity and new therapeutic options. Am. J. Hematol. 89:1121–1131, 2014. © 2014 Wiley Periodicals, Inc.